Clinical outcomes associated with complementary and alternative medicine-related "immunity-boosting" practices in patients with cirrhosis during the COVID-19 pandemic - an observational study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
24 Mar 2023
24 Mar 2023
Historique:
medline:
28
3
2023
entrez:
24
3
2023
pubmed:
25
3
2023
Statut:
ppublish
Résumé
During the coronavirus disease 2019 pandemic, Ayurvedic herbal supplements and homeopathic immune boosters (IBs) were promoted as disease-preventive agents. The present study examined the clinical outcomes among patients with chronic liver disease who presented with complications of portal hypertension or liver dysfunction temporally associated with the use of IBs in the absence of other competing causes. This single-center retrospective observational cohort study included patients with chronic liver disease admitted for the evaluation and management of jaundice, ascites, or hepatic encephalopathy temporally associated with the consumption of IBs and followed up for 180 days. Chemical analysis was performed on the retrieved IBs. From April 2020 to May 2021, 1022 patients with cirrhosis were screened, and 178 (19.8%) were found to have consumed complementary and alternative medicines. Nineteen patients with cirrhosis (10.7%), jaundice, ascites, hepatic encephalopathy, or their combination related to IBs use were included. The patients were predominantly male (89.5%). At admission, 14 (73.75%) patients had jaundice, 9 (47.4%) had ascites, 2 (10.5%) presented with acute kidney injury, and 1 (5.3%) had overt encephalopathy. Eight patients (42.1%) died at the end of the follow up period. Hepatic necrosis and portal-based neutrophilic inflammation were the predominant features of liver biopsies. IB analysis revealed detectable levels of (heavy metals) As (40%), Pb (60%), Hg (60%), and various hepatotoxic phytochemicals. Ayurvedic and Homeopathic supplements sold as IBs potentially cause the worsening of preexisting liver disease. Responsible dissemination of scientifically validated, evidence-based medical health information from regulatory bodies and media may help ameliorate this modifiable liver health burden.
Identifiants
pubmed: 36961176
doi: 10.1097/MD.0000000000033365
pii: 00005792-202303240-00047
pmc: PMC10035553
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e33365Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/ . Retrieved on November 24, 2021.
Lotfi M, Hamblin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020;508:254–66.
Wang C, Wang Z, Wang G, et al. COVID-19 in early 2021: current status and looking forward. Signal Transduct Target Ther. 2021;6:114.
Wagner DN, Marcon AR, Caulfield T. “Immune boosting” in the time of COVID: selling immunity on instagram. Allergy Asthma Clin Immunol. 2020;16:76.
Rachul C, Marcon AR, Collins B, et al. COVID-19 and “immune boosting” on the internet: a content analysis of Google search results. BMJ Open. 2020;10:e040989.
Guidelines for AYUSH practitioners for COVID-19. Available at: https://www.ayush.gov.in/ayush-guidelines.html . Retrieved on November 29, 2021.
Philips CA, Abraham L. Tinospora cordifolia (Giloy) and autoimmune-like liver injury - a classic case of primum non nocere, “first, do no harm.” [published online ahead of print, 2021 Sep 4]. J Clin Exp Hepatol. 2021;12:245–6.
Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induced acute-on-chronic liver failure in Asian patients. Am J Gastroenterol. 2019;114:929–37.
Philips CA, Paramaguru R, Joy AK, et al. Clinical outcomes, histopathological patterns, and chemical analysis of ayurveda and herbal medicine associated with severe liver injury-a single-center experience from southern India. Indian J Gastroenterol. 2018;37:9–17.
Philips CA, Paramaguru R, Augustine P, et al. A single-center experience on outcomes of complementary and alternative medicine use among patients with cirrhosis. Hepatol Commun. 2019;3:1001–12.
Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-induced liver injury: a case series from Iceland and the US drug-induced liver injury network. Liver Int. 2020;40:825–9.
Weber S, Gerbes AL. Ashwagandha-induced liver injury: self-reports on commercial websites as useful adjunct tools for causality assessment. Am J Gastroenterol. 2021;116:2151–2.
Chopra A, Saluja M, Tillu G, et al. Evaluating higher doses of Shunthi - Guduchi formulations for safety in treatment of osteoarthritis knees: a Government of India NMITLI arthritis project. J Ayurveda Integr Med. 2012;3:38–44.
Lombardi N, Crescioli G, Maggini V, et al. Acute liver injury following turmeric use in Tuscany: an analysis of the Italian Phytovigilance database and systematic review of case reports. Br J Clin Pharmacol. 2021;87:741–53.
Luber RP, Rentsch C, Lontos S, et al. Turmeric induced liver injury: a report of two cases. Case Reports Hepatol. 2019;2019:6741213.
Lee BS, Bhatia T, Chaya CT, et al. Autoimmune hepatitis associated with turmeric consumption. ACG Case Rep J. 2020;7:e00320.
Björnsson ES, Navarro VJ, Chalasani N. Liver injury following tinospora cordifolia consumption: drug induced AIH, or de novo AIH? J Clin Exp Hepatol. 2021;12:6–9.
Daswani PG, Gholkar MS, Birdi TJ. Psidium guajava: a single plant for multiple health problems of rural Indian population. Pharmacogn Rev. 2017;11:167–74.
Attawish A, Chavalittumrong P, Rugsamon P, et al. Toxicity study of psidium guajava Linn. Leaves. Warasan Krom Witthayasat Kan Phaet. 1995;37:289–305.
Zárybnický T, Boušová I, Ambrož M, et al. Hepatotoxicity of monoterpenes and sesquiterpenes. Arch Toxicol. 2018;92:1–13.
Hudson A, Lopez E, Almalki AJ, et al. A review of the toxicity of compounds found in herbal dietary supplements. Planta Med. 2018;84:613–26.
Quan NV, Dang Xuan T, Teschke R. Potential hepatotoxins found in herbal medicinal products: a systematic review. Int J Mol Sci . 2020;21:5011.
Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology. 2017;65:363–73.
Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines. Hepatol Int. 2021;15:258–82.
Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71:306–33.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154–81.
Philips CA, Rajesh S, George T, et al. Outcomes and toxicology of herbal drugs in alcoholic hepatitis - a single center experience from India. J Clin Transl Hepatol. 2019;7:329–40.